Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER’s Outlook problems

Executive Summary

Some senior FDA officials failed to publicize meetings, as required, from January 1999 through December of 2006, according to reports compiled by House Energy and Commerce Republican staffers. The calendar listings, reviewed in preparation for hearings on drug safety legislation, contained three entries for former CDER Director Janet Woodcock and none for her successor, Steven Galson, as well as missing data for former Deputy Commissioner Scott Gottlieb and other center directors, the report shows. FDA admitted that public calendar listings "were not as inclusive as they should have been because of administrative oversight." Unreported meetings are now being added, according to a written response from the agency to the House committee. As opposed to the drug officials, listings for the Director for Veterinary Medicine Stephen Sundlof contain 263 publicized meetings during the studied time frame...

You may also be interested in...



RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

JHL Becomes Eden And Announces Denosumab Progress

Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.

Australia’s Starpharma Plans To Launch COVID-Killing Nasal Spray In Europe

Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel